By Sam Boughedda
Investing.com — Barring a reversal, Biogen Inc (NASDAQ:BIIB) stock is set to close down for the third consecutive day after it was reported that the company is investigating the death of a 75-year-old patient after he recently received the company's Aduhelm Alzheimer's drug.
According to a report in The Wall Street Journal, the patient was hospitalized and diagnosed with brain swelling after taking the recently approved drug.
Biogen set it is not yet known if the brain swelling was related to Aduhelm.
"All the recently published cases related to Aduhelm are under careful review as well as medical evaluation, including the fatal case of a 75-year-old patient whose cause of death remains under investigation and who was diagnosed during hospitalization with cerebral edema thought to be ARIA-E," the company was quoted as saying.
Biogen shares are currently down 1.3% on Tuesday, adding to Monday's more than 2% decline.